JP2018504122A - 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 - Google Patents

免疫調節特性が増加した細胞ならびにその使用および製造のための方法 Download PDF

Info

Publication number
JP2018504122A
JP2018504122A JP2017539018A JP2017539018A JP2018504122A JP 2018504122 A JP2018504122 A JP 2018504122A JP 2017539018 A JP2017539018 A JP 2017539018A JP 2017539018 A JP2017539018 A JP 2017539018A JP 2018504122 A JP2018504122 A JP 2018504122A
Authority
JP
Japan
Prior art keywords
cells
population
pge
cell
hematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017539018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504122A5 (enExample
Inventor
デイビッド ロビンス，
デイビッド ロビンス，
ベッツィー レズナー，
ベッツィー レズナー，
リー ミッチェル，
リー ミッチェル，
リサ ゲレタズ，
リサ ゲレタズ，
フィリップ アレサンドロ パロネ，
フィリップ アレサンドロ パロネ，
ロバート スティーブン タケ，
ロバート スティーブン タケ，
ケビン ライ，
ケビン ライ，
バーラム バラマール，
バーラム バラマール，
Original Assignee
フェイト セラピューティクス，インコーポレイテッド
フェイト セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェイト セラピューティクス，インコーポレイテッド, フェイト セラピューティクス，インコーポレイテッド filed Critical フェイト セラピューティクス，インコーポレイテッド
Publication of JP2018504122A publication Critical patent/JP2018504122A/ja
Publication of JP2018504122A5 publication Critical patent/JP2018504122A5/ja
Priority to JP2020201293A priority Critical patent/JP7304844B2/ja
Priority to JP2023025696A priority patent/JP2023062155A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/71—Oxidoreductases (EC 1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017539018A 2015-01-26 2016-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 Withdrawn JP2018504122A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020201293A JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107517P 2015-01-26 2015-01-26
US62/107,517 2015-01-26
US201562112653P 2015-02-06 2015-02-06
US62/112,653 2015-02-06
PCT/US2016/014942 WO2016123117A1 (en) 2015-01-26 2016-01-26 Cells with increased immuno-regulatory properties and methods for their use and manufacture

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020201294A Division JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201293A Division JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Publications (2)

Publication Number Publication Date
JP2018504122A true JP2018504122A (ja) 2018-02-15
JP2018504122A5 JP2018504122A5 (enExample) 2019-03-07

Family

ID=56544240

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539018A Withdrawn JP2018504122A (ja) 2015-01-26 2016-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201294A Pending JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201293A Active JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023010327A Pending JP2023052658A (ja) 2015-01-26 2023-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A Pending JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020201294A Pending JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201293A Active JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023010327A Pending JP2023052658A (ja) 2015-01-26 2023-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A Pending JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Country Status (7)

Country Link
US (6) US20180112180A1 (enExample)
EP (2) EP3250682A4 (enExample)
JP (5) JP2018504122A (enExample)
CN (2) CN112481211B (enExample)
AU (3) AU2016211688A1 (enExample)
CA (1) CA2974903A1 (enExample)
WO (1) WO2016123117A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512658A (ja) * 2018-10-10 2022-02-07 ノース カロライナ ステート ユニバーシティ Ｐｄ－ｌ１提示血小板は、新たに発症する１型糖尿病を逆転させる
JP2022539249A (ja) * 2019-07-05 2022-09-07 ケース ウェスタン リザーブ ユニバーシティ 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114058582A (zh) 2015-01-26 2022-02-18 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
KR20180033537A (ko) 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도
CN115927199A (zh) 2015-11-04 2023-04-07 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017127729A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CA3065945A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
CN107714717A (zh) * 2017-10-11 2018-02-23 刘志强 聚肌胞苷酸在制备治疗或预防结肠炎的药物中的应用
EP3752598B1 (en) * 2018-02-16 2022-11-02 NextCell Pharma AB Allogeneic composition
KR20210075136A (ko) * 2018-10-12 2021-06-22 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 면역 검출 및 자가면역을 회피하는 세포, 섬 및 오르가노이드, 그의 생산 및 사용 방법
CN109706180A (zh) * 2019-01-11 2019-05-03 杭州荣泽生物科技有限公司 一种脐带间充质干细胞过表达ido增强免疫抑制的方法及应用
WO2020163868A1 (en) * 2019-02-09 2020-08-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically modified hematopoietic stem and progenitor cells (hspcs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu and dysregulated niches
US20230119606A1 (en) * 2020-02-18 2023-04-20 Octagon Therapeutics, Inc. Immune cell modulators
EP4171589A4 (en) * 2020-06-26 2024-07-17 The Children's Medical Center Corporation Methods and compositions for treating multiple sclerosis
WO2022011010A1 (en) * 2020-07-08 2022-01-13 The Jackson Laboratory Transgenic mouse model expressing human hla-a201 restriction gene
WO2022202352A1 (ja) 2021-03-24 2022-09-29 キヤノン株式会社 虚像光学系、それを備える虚像表示装置及び車載システム
KR20220162394A (ko) * 2021-06-01 2022-12-08 에스씨엠생명과학 주식회사 기능강화 줄기세포 및 조절 t 세포를 포함하는 아토피 피부염 예방 또는 치료용 병용투여 조성물
WO2025043075A1 (en) * 2023-08-24 2025-02-27 The Johns Hopkins University Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury
WO2025199431A1 (en) * 2024-03-22 2025-09-25 Colorado State University Research Foundation Innate immune pathway activated mesenchymal stromal cells for treatment of musculoskeletal disorders or conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508818A (ja) * 2006-11-03 2010-03-25 アストロム バイオサイエンシーズ， インコーポレイテッド 組織修復のための混合細胞集団および細胞処理のための単離技術
US20140234373A1 (en) * 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US7763251B2 (en) * 2002-04-12 2010-07-27 Medical College Of Georgia Research Institute, Inc. Kits to assess the risk of tumor progression
EP2177601A1 (en) * 2002-04-12 2010-04-21 Medical College of Georgia Research Institute, Inc Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005040391A1 (en) 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
US7592177B2 (en) 2003-11-10 2009-09-22 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
CN101932705A (zh) 2007-04-07 2010-12-29 怀特黑德生物医学研究所 体细胞重编程
CA2697265A1 (en) * 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
SG10202103401QA (en) 2008-03-17 2021-05-28 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
BRPI0920679A2 (pt) * 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
WO2010054271A1 (en) 2008-11-06 2010-05-14 Indiana University Research & Technology Corporation Materials and methds to enhance hematopoietic stem cells engraftment procedures
WO2010077955A1 (en) 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
NZ597804A (en) * 2009-07-24 2013-10-25 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
ES2938049T3 (es) 2009-10-16 2023-04-04 Scripps Research Inst Inducción de células pluripotentes
US20120251514A1 (en) * 2009-11-13 2012-10-04 University Health Network Modulated programmed death ligand-1
AU2010341703B2 (en) * 2009-12-08 2016-01-21 The Board Of Trustees Of The University Of Illinois Stem cell immune modulation methods of use and apparatus
MX362513B (es) * 2010-03-23 2019-01-22 Intrexon Corp Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
NZ737844A (en) * 2010-03-26 2022-09-30 Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20140030232A1 (en) * 2010-08-12 2014-01-30 Fate Therapeutics, Inc. Hematopoietic stem and progenitor cell therapy
AU2012321088B8 (en) * 2011-12-02 2016-12-15 Fate Therapeutics, Inc. Enhanced stem cell composition
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
KR20180033537A (ko) * 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508818A (ja) * 2006-11-03 2010-03-25 アストロム バイオサイエンシーズ， インコーポレイテッド 組織修復のための混合細胞集団および細胞処理のための単離技術
US20140234373A1 (en) * 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL STEM CELL, vol. 9, JPN6019042815, 2011, pages 119 - 130, ISSN: 0004318676 *
EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 43, no. 8, JPN6019042819, 2011, pages 446 - 454, ISSN: 0004318678 *
IMMUNOBIOLOGY, vol. 215, JPN6019042812, 2010, pages 452 - 457, ISSN: 0004318675 *
JOURNAL OF LEUKOCYTE BIOLOGY, vol. 88, JPN6019042817, 2010, pages 1241 - 1249, ISSN: 0004318677 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512658A (ja) * 2018-10-10 2022-02-07 ノース カロライナ ステート ユニバーシティ Ｐｄ－ｌ１提示血小板は、新たに発症する１型糖尿病を逆転させる
JP2022539249A (ja) * 2019-07-05 2022-09-07 ケース ウェスタン リザーブ ユニバーシティ 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法
JP7668781B2 (ja) 2019-07-05 2025-04-25 ケース ウェスタン リザーブ ユニバーシティ 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法

Also Published As

Publication number Publication date
US20250101381A1 (en) 2025-03-27
US20180112180A1 (en) 2018-04-26
AU2021203480A1 (en) 2021-07-01
AU2021202391A1 (en) 2021-05-20
JP2023062155A (ja) 2023-05-02
CA2974903A1 (en) 2016-08-04
CN112481211A (zh) 2021-03-12
CN107429232A (zh) 2017-12-01
US20250333702A1 (en) 2025-10-30
US20230002733A1 (en) 2023-01-05
AU2021202391B2 (en) 2023-10-12
US20200102540A1 (en) 2020-04-02
JP2021050220A (ja) 2021-04-01
EP3250682A1 (en) 2017-12-06
JP2023052658A (ja) 2023-04-11
US20200172870A1 (en) 2020-06-04
CN112481211B (zh) 2024-07-05
EP3770252A1 (en) 2021-01-27
WO2016123117A1 (en) 2016-08-04
AU2016211688A1 (en) 2017-08-10
EP3250682A4 (en) 2018-08-01
JP2021048862A (ja) 2021-04-01
JP7304844B2 (ja) 2023-07-07
CN107429232B (zh) 2023-01-03

Similar Documents

Publication Publication Date Title
JP7304844B2 (ja) 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
US20220090008A1 (en) Colony forming medium and use thereof
US20190119635A1 (en) Modulation of t lymphocytes
JP7668781B2 (ja) 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法
EP2968416A1 (en) Cell potency assay for therapeutic potential
JP7614106B2 (ja) 造血幹細胞の拡大
JP6444448B2 (ja) 骨芽細胞機能を増加させる方法
KR20240001173A (ko) 중간엽 계통 전구체 또는 줄기 세포를 이용하는 특정 환자의 급성 호흡 곤란 증후군(ards)의 치료 방법
HK40046349A (en) Cells with increased immuno-regulatory properties and methods for their use and manufacture
US20230303973A1 (en) Generation of tumor immunity using astrocytes and astrocyte-dendritic cell combinations
Lanza et al. Immunosuppressive properties of mesenchymal stromal cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201210

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201211

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20201216